Back to Results

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Interested in this Trial?

Contact Us

Trial Status Terminated

Trial Identifier

NCT00802893

Condition

Endothelial Dysfunction, Isolated Systolic Hypertension

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.

Eligibility Criteria

Birth Sex

All

Age

From 40 Years

Healthy Volunteers

No

Drug/Treatment:

6R-BH4, Placebo

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

3

Study Started:

2008-12

Study Updated:

2017-08-21

Trial Locations

  • Johns Hopkins University

    Baltimore, Maryland, United States

Inclusion Criteria

  • No change in prescribed antihypertension medications within the previous 30 days
  • Study staff able to visualize and measure the brachial artery diameter by high resolution vascular ultrasound required for FMD measurements
  • ISH with the following mean seated BP: SBP > 145 and < 180 mmHg. Diastolic blood pressure < 90mmHg

Exclusion Criteria

  • Has known hypersensitivity to 6RBH4 or its excipients
  • Pregnant or breastfeeding at screening
  • Use of any investigational product or investigational medical device within 30 days prior to screening
  • Current disease or condition that would interfere with study participation or safety such as the following: heart failure, atrial fibrillation, aortic valve disease, bleeding disorders, history of repeated syncope or vertigo, severe GERD, GI ulcer, symptomatic coronary or peripheral vascular disease, arrhythmia, serious neurologic disorders including seizures, organ transplant or organ failure
  • Hypertension secondary to other medical conditions
  • Any severe comorbid condition that would limit life expectancy to <6 months
  • Current use of any nicotine containing substances
  • History of drug or alcohol abuse
  • MI, stroke or surgery within 90 days before Screening Visit
  • CABG within 6 months before the Screening Visit
  • Serum creatinine >2.0mg/dl or AST, ALT, GGT levels >2times upper limit of normal
  • Concomitant treatment with: any drug known to inhibit folate metabolism, any phosphodiesterase-5 or -3 inhibitor
  • Previous treatment with any formulation of BH

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us